WSGR represents Pharmacyclics in $21 billion sale to AbbVie
Wilson Sonsini Goodrich & Rosati provided counsel to Sunnyvale-based Pharmacyclics Inc. in its $21 billion sale to AbbVie Inc. The North Chicago-based biopharmaceutical company is purchasing Pharmacyclics’ flagship product, Imbruvica, as a result of the sale. Imbruvica treats tumors that affect blood, bone marrow and lymphatic systems. AbbVie will pay $261.25 per share, in an offer the includes both cash and stock.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
